Table 3 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Open Access
- 1 July 2026
- other
- Published by American Association for Cancer Research (AACR)